Fount Therapeutics Secures $22M Series A Financing

Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas. The first “NewCo”, Kinnate, will be focused on developing precision oncology treatments.